TORONTO, June 23,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
cannabis throughout Latin America
and Europe, announces the results
of its 2022 Annual General and Special Meeting of shareholders (the
"Meeting") held on June 23, 2022.
Shareholders approved all of the resolutions detailed in the
management information circular of the Company dated May 17, 2022, namely:
- the re-appointment of BDO Canada LLP as auditors of the Company
for the ensuing year and authorizing the directors to determine the
remuneration for their services;
- fixing the number of directors to be elected at the Meeting at
six (6);
- the election of all of the six (6) management nominees to the
board of directors of the Company (the "Board of Directors"),
including Juan Carlos Echeverry,
Vicente Fox, Christopher Naprawa, Deborah Rosati, Alvaro
Torres and Alvaro Yanez;
- the ratification of the amended and restated stock option plan
of the Company; and
- the ratification of the amended and restated RSU plan of the
Company.
The number of common shares of the Company ("Common Shares")
represented at the Meeting was 44,108,709 or 23.751% of the issued
and outstanding Common Shares as of the record date.
The Company further announces that, after the completion of the
Meeting, Ms. Deborah Rosati resigned
from the Board of Directors and her positions on all committees of
the Board of Directors, effective immediately. Mr. Naprawa,
Chairman of the Company stated, "On behalf of the Board of
Directors, I would like to sincerely and personally thank Deborah
for her valuable contribution to our Company over the years and
wish her all the best."
About Khiron Life Sciences
Corp.
Khiron is a leading vertically integrated international medical
cannabis corporation with core operations in Latin America and Europe. Leveraging medical health clinics and
proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs,
scientific, product innovation, and cannabis operations expertise
to drive prescriptions and brand loyalty with patients worldwide.
The Company has a sales presence in Colombia, Peru, Germany, United
Kingdom, and Brazil and is
positioned to commence sales in Mexico. The Company is led by co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at https://investors.khiron.ca.
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information and statements contained herein reflect management's
current beliefs and is based on information currently available and
on assumptions that management believes to be reasonable. These
assumptions include, but are not limited to, assumptions regarding
the future regulatory developments and economic conditions, the
Company's ability to continue its growth and reduce costs. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, estimates or opinions, future events or results or
otherwise or to explain any material difference between subsequent
actual events and such forward-looking information, except as
required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-announces-results-of-2022-annual-general-and-special-meeting-301574437.html
SOURCE Khiron Life Sciences Corp.